Pfizer Inc. Announces Q2 2026 Quarterly Results (8-K Filed Aug 4, 2026)

What Happened

• Pfizer Inc. announced its second-quarter 2026 financial results in a press release dated August 4, 2026 and filed those results on Form 8‑K (Item 2.02). The press release is furnished as Exhibit 99 to the 8‑K and the filing includes the Inline XBRL cover page (Exhibit 104). The report was signed by Margaret M. Madden, Senior Vice President and Corporate Secretary, on August 4, 2026.

Key Details

• Filing date: August 4, 2026 (Form 8‑K).
• Item reported: 2.02 Results of Operations and Financial Condition — press release announcing Q2 2026 results (Exhibit 99).
• Technical exhibit: 104 Cover Page Interactive Data File — Inline XBRL tags embedded on the cover page.
• Signature: Signed by Margaret M. Madden, Senior Vice President and Corporate Secretary.

Why It Matters

• The 8‑K notifies investors that Pfizer has publicly released its Q2 2026 earnings and related financial information; the press release will contain the company’s reported revenue, earnings, and any commentary or guidance management chose to disclose.
• Investors should review the Exhibit 99 press release (and any related earnings materials) for the specific quarterly results, revenue and EPS figures, and any forward-looking statements, since those numbers are material to valuation and portfolio decisions.